Lineage Cell Therapeutics, Inc. (LCTX)

Market Cap	251.39M -36.4%
Revenue (ttm)	13.08M +19.9%
Net Income	-32.26M
EPS	-0.19
Shares Out	252.91M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,158,177
Open	1.0100
Previous Close	1.0300
Day's Range	0.9837 - 1.0250
52-Week Range	0.8823 - 2.0900
Beta	1.60
Analysts	Strong Buy
Price Target	5.50 (+453.32%)
Est. Earnings	Nov 5, 2026

About LCTX

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1990
• Employees: 77
• Stock Exchange: NYSE American
• Ticker Symbol: LCTX
• Website: https://www.lineagecell.com

Financial Performance

In 2025, Lineage Cell Therapeutics's revenue was $14.56 million, an increase of 53.24% compared to the previous year's $9.50 million. Losses were -$63.53 million, 241.4% more than in 2024.

Analyst Summary

According to 7 analysts, the average rating for LCTX stock is "Strong Buy." The 12-month stock price target is $5.5, which is an increase of 453.32% from the latest price.

Price Target

$5.5

(453.32% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 10, 2026

Data Sources Report a data error